Sanjivani ParanteralQ3 FY24

Sanjivani Paranteral Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹166.8P/E: 20.6Market Cap: ₹205 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • The company is poised to report good results and revenues in the coming years, supported by strong tie-ups and good market access.
  • Dehradun facility upgradation is underway, with upcoming inspections expected to enable approvals in multiple Latin American countries and potentially East European countries by end of 2024, expanding market reach.
  • Focus on expanding export markets, especially in Latin America, Francophone Africa, and East Africa, targeting new countries for growth.
  • Management team expansion with addition of 15-20 senior management personnel will support scaling operations.
  • Continued product portfolio expansion with 15-20 new products annually, adding to injectables and orals, primarily targeting chronic diseases.
  • Capacity utilization is growing, with injectables at 70% and orals at 35%, and an expectation of sustained growth in injectables.
  • Government tenders and private markets are competitive, with some regions having stable or growing market share.
  • The company aims to maintain a 75% export and 25% domestic revenue mix.

See what Sanjivani Paranteral management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • The transcript does not explicitly mention any current or planned fundraising through debt or equity.
  • However, it mentions company expansion plans including management team growth and plant upgrades.
  • Ashwani Khemka mentioned expansion of the management team in light of a "fundraiser," indicating some form of capital raising is planned or ongoing, but details such as amount, type (debt/equity), or timing are not provided.
  • The company is investing in new facilities such as the Hindustan Antibiotic JV with a total capex of around INR 35 to 38 crores, with about 10% spent so far.
  • No specific fundraising details like amounts or instruments were disclosed in this call transcript.

See what Sanjivani Paranteral management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Total capex for Hindustan Antibiotic Limited (HAL) JV: INR 35-38 crores; 10% invested so far; 70% of major equipment ordered; plant layout finalizing; civil work to start soon; revenue expected from Q4 FY25.
  • Prague facility capex: INR 3 to 3.5 crores already spent; includes packaging line delayed to late March due to Red Sea embargo; targeting entry into European and American markets.
  • Current facility upgrades (Dehradun and Mumbai): INR 4-5 crores planned; includes regulatory approvals and capacity enhancements.
  • Financing through preference shares and internal accruals; working with HR firm to expand senior management in line with fundraising.
  • Strategic investments to access regulated and semi-regulated markets, expanding product portfolio and market presence.

Track Sanjivani Paranteral — get its next earnings analysis in your feed

How does Sanjivani Paranteral rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSanjivani Paranteral
Rev 2Mar 3

How does Sanjivani Paranteral rank in Pharmaceuticals & Biotechnology?

Compare Sanjivani Paranteral against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →